Experts Hetty Carraway and Justin Taylor discuss improving drug approvals in MDS. They cover challenges of treating high-risk disease, novel targets of interest, and more. Collaboration between NCI and cooperative groups in clinical trials, biomarker significance, accelerating drug approvals, and individualizing treatment strategies are also explored.